Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAC 1

Drug Profile

VAC 1

Alternative Names: Antigen-presenting autologous dendritic cells - Lineage Cell Therapeutics; AST-VAC1; Cancer vaccine - Argos/Geron; GRNVAC 1; hTERT RNA vaccine - Argos/Geron; RNA-loaded autologous dendritic cell vaccine - Argos/Geron; VAC1

Latest Information Update: 06 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Argos Therapeutics Inc; Geron Corporation
  • Developer Asterias Biotherapeutics; Lineage Cell Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics
  • 11 Mar 2019 Asterias Biotherapeutics has been acquired and merged into BioTime
  • 28 Mar 2017 Asterias Biotherapeutics has patent protection for VAC 1 in South Korea, Israel, Singapore and other jurisdictions (Asterias Biotherapeutics form 10-k, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top